The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
 
Nobuaki Mamesaya
Honoraria - AstraZeneca Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tomoya Fukui
Honoraria - AstraZeneca Japan; Boehringer-Ingelheim Japan Inc.; Chugai Pharma; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical Co. Ltd..
 
Toshiaki Takahashi
Honoraria - Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD K.K.; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K. (Inst); Pfizer (Inst)
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Takahiro Yoshizawa
No Relationships to Disclose
 
Takaaki Tokito
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical
 
Koichi Azuma
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Kei Morikawa
Research Funding - DNA Chip Research Inc., Tokyo, Japan. (Inst)
 
Yusuke Okuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takashi Kasai
No Relationships to Disclose
 
Ken Masubuchi
No Relationships to Disclose
 
Shinji Nakamichi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Taiho Pharmaceutical
 
Masaharu Aga
No Relationships to Disclose
 
Jiichiro Sasaki
No Relationships to Disclose
 
Satoshi Igawa
No Relationships to Disclose
 
Akiko Kada
No Relationships to Disclose
 
Katsuhiko Naoki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Parexel/CALYX (Inst); Taiho Pharmaceutical (Inst)
 
Hiroaki Okamoto
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)